2
Clinical Trials associated with ASKG-915注射用ASKG915单药治疗在晚期实体瘤患者中安全性、耐受性及药代动力学的Ⅰ期临床研究
[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of ASKG915 monotherapy for injection in patients with advanced solid tumors
注射用ASKG915单药治疗在晚期实体瘤患者中安全性、耐受性、药代动力学、免疫原性、PD特性、抗肿瘤疗效以及II期推荐剂量(RP2D)。
[Translation] Safety, tolerability, pharmacokinetics, immunogenicity, PD properties, anti-tumor efficacy, and Phase II recommended dose (RP2D) of ASKG915 monotherapy for injection in patients with advanced solid tumors.
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 as a Single Agent in Patients With Selected Advanced Solid Tumors.
The study is a Phase 1dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent in patients with selected advanced solid tumors.
100 Clinical Results associated with ASKG-915
100 Translational Medicine associated with ASKG-915
100 Patents (Medical) associated with ASKG-915
100 Deals associated with ASKG-915